SAN DIEGO, Jan. 16, 2018 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a
company developing intratumoral cancer immunotherapies, today
announced the appointment of Gregory T.
Mayes to its board of directors. Mr. Mayes
is President, Chief Executive Officer and Founder of Engage
Therapeutics, and brings over 20 years of experience as a
biopharmaceutical executive with an extensive network in the life
sciences field to OncoSec's board of directors. The Company's Board
appointed him on Friday, January 12,
2018.
"We are extremely pleased to have Greg join our board of
directors at this pivotal time for the Company," said Daniel J. O'Connor, Chief Executive Officer of
OncoSec. "With his well-established track record of success, we
believe Greg's deep business, legal and board level expertise will
provide valuable insight as we continue to advance our lead
program."
"The field of intratumoral immunotherapy is at an exciting
juncture and I believe OncoSec has established a unique and
innovative approach to addressing a significant unmet medical need
for patients who do not currently respond to anti-PD-1 treatments
with their ImmunoPulse platform," said Mayes. "I look forward to
contributing to the advancement of the Company's
technology."
Mr. Mayes is the President, Chief Executive Officer and Founder
of Engage Therapeutics, a clinical-stage biopharmaceutical company
developing Staccato® alprazolam, a small, easy-to-use
hand-held drug-device combination product with the potential to
become the first product approved to abort an active epileptic
seizure when a predictable seizure pattern emerges.
Prior to Engage Therapeutics, Mr. Mayes served as Chief
Operating Officer of Advaxis Immunotherapies, and a member of its
board of directors. While at Advaxis, Mr. Mayes was
instrumental in establishing major pharma partnerships and
developing a Phase 3 registration strategy and clinical development
plan for the Company's lead product candidate, which resulted in an
FDA Special Protocol Assessment and Fast Track Designation.
Prior to Advaxis, Mr. Mayes served as the President and
General Counsel and Board member for Unigene Laboratories where he
led out-licensing efforts for a novel oral peptide drug delivery
platform. Mr. Mayes also served as Vice President, General Counsel,
and Chief Compliance Officer at ImClone Systems, an Eli Lilly
subsidiary, where his contributions significantly contributed to
the clinical development and commercialization of ERBITUX®
(cetuximab), and the $6.5
billion-dollar sale of the Company to Eli Lilly in 2008. Mr.
Mayes also served as Senior Counsel at AstraZeneca Pharmaceuticals
LP, where he provided a wide range of legal services in connection
with the development and commercialization of five approved
products in the Company's oncology portfolio. Mayes is a cum
laude graduate of Syracuse University
where he was recognized as a Remembrance Scholar and he earned his
J.D. degree magna cum laude from Temple
University School of Law, where he was the Articles Editor
on the Temple Law Review.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as plasmid encoded IL-12
(tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable
safety profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "can," "may," "will," "suggest," "look
forward to," "potential," "understand," and similar references to
future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data, safety
and technical issues; our ability to raise additional funding
necessary to fund continued operations; and the other factors
discussed in OncoSec's filings with the Securities and Exchange
Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
CONTACT:
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
Stern Strategy Group
Brian Hyland or Ashley Duvall
Phone: (908) 276-4344
OncoSecPR@sternstrategy.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-appoints-veteran-biopharma-executive-gregory-t-mayes-to-board-of-directors-300582986.html
SOURCE OncoSec Medical Incorporated